Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
10/2008
10/16/2008US20080255154 Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes
10/16/2008US20080255109 Antigonadotrophins; breast and prostate cancer, endometriosis, benign prostate hyperplasia; regulation of fertility; 4-(3-Chloro-4-{{(4-chloro-benzenesulfonyl)-methyl-amino]-methyl}-thiophene-2-carbonyl)-3,4-dihydro-2H-benzo[1,4]oxazine-2carboxylic acid (3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-amide
10/15/2008EP1979359A1 Process for the preparation of rapamycin derivatives
10/15/2008EP1978967A1 Quinazolinone derivatives as vanilloid antagonists
10/15/2008EP1603901B1 Tetrahydropyran compounds as tachykinin antagonists
10/15/2008EP1567520B1 Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
10/15/2008EP1319008B1 Water soluble rapamycin esters
10/15/2008EP1308439B1 Proline derivatives and use thereof as drugs
10/15/2008CN100425594C PPAR-activating compound and pharmaceutical composition comprising the compound
10/14/2008US7435820 Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use
10/14/2008US7435743 I kappa B kinase beta inhibitors that are 2-amino-4,6-disubstituted nicotinic acid ester analogs; antiinflammatory, antitumor and antiischemic effects; asthma; nuclear factor kappa B inhibitors; 7-(2-hydroxyphenyl)-5-(3-piperidinyl)-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one
10/14/2008US7435728 Pyrazole derivatives
10/14/2008CA2275351C Novel counterparts of camptothecin, their application as medicine and pharmaceutical compositions containing them
10/09/2008WO2008120003A1 Substituted piperidines for use in the treatment of bacterial infections
10/09/2008WO2008119663A1 Heterocyclic antiviral compounds
10/09/2008WO2008086510A3 Process to make lestaurtinib
10/09/2008WO2008057873A3 Inhibitors of hepatitis c virus
10/09/2008WO2008057871A3 Inhibitors of hepatitis c virus
10/09/2008WO2007124424A3 Il-8 receptor antagonists
10/09/2008US20080249086 N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}methane-sulfonamide; trial and ventricular arrhythmias; pharmacokinetics; electrophysiological activity; lowering daily clinical dose, lengthening duration of action; side effect reduction; arrhythmia
10/09/2008US20080249085 for treating cell proliferative diseases; maytansinoid analogs; with lower systemic toxicity, improved pharmacokinetic profile, and better clinical activity; inhibiting fungal growth; compounds can target tubulin, Heat Shock Protein-90
10/09/2008CA2682639A1 Heterocyclic antiviral compounds
10/08/2008EP1978095A1 Chimeric receptor proteins for controlling signal transduction and ligands binding thereto
10/08/2008EP1978012A1 Alternative synthesis of renin inhibitors and intermediates thereof
10/08/2008EP1976855A1 1-aza-3,7-dioxabicyclo[3.3.0]octane compounds and their use as pro-fragrances
10/08/2008EP1735321B1 Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
10/08/2008EP1678185B1 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole compounds for the treatment of tuberculosis
10/08/2008EP1485363B1 Cyclic amides
10/08/2008EP1389100B1 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
10/08/2008CN101282981A Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
10/08/2008CN101279983A 抗肿瘤联合药物 Joint anti-tumor drugs
10/08/2008CN101279977A Refining method of benemicin raw material and benemicin solution prepared from the benemicin raw material
10/07/2008US7432375 JNK inhibitors
10/07/2008US7432283 Heterocyclic GABAA subtype selective receptor modulators
10/07/2008US7432278 Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents
10/07/2008US7432270 N-aroyl cyclic amines
10/07/2008US7432074 Method for extracting a macrolide from biomatter
10/02/2008WO2008118718A2 2-aminopyridine analogs as glucokinase activators
10/02/2008WO2008118122A2 Compounds and amyloid probes thereof for therapeutic and imaging uses
10/02/2008WO2007117591A9 Total synthesis of salinosporamide a and analogs thereof
10/02/2008DE19702537B4 Asymmetrische Dioxazinverbindungen, Zwischenprodukte dafür und Aufbringung der asymmetrischen Dioxazinverbindungen Asymmetric dioxazine compounds, intermediates therefor and application of the asymmetric dioxazine
10/02/2008CA2682221A1 Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
10/02/2008CA2681695A1 2-aminopyridine analogs as glucokinase activators
10/01/2008EP1973919A2 One pot synthesis of tetrazole derivatives of sirolimus
10/01/2008EP1973913A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives
10/01/2008EP1973902A2 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
10/01/2008EP1973898A1 Pdf inhibitors
10/01/2008EP1732922B1 Methods for minimizing thioamide impurities
10/01/2008CN101277963A Benzimidazole derivatives as SIRTUIN modulators
10/01/2008CN101277960A Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
10/01/2008CN101277939A Acyclic ikur inhibitors
10/01/2008CN100422181C [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
09/2008
09/30/2008US7429597 Heterobicyclic compound such as quinazoline anticoagulants and factor X inhibitors
09/30/2008US7429582 e.g. N,N-dimethyl-1-[6-(1-naphthylsulfonyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indazol-2-yl]-methanamine; serotonin receptor antagonist; antidepressant, epilepsy, schizophrenia, hyperactivity
09/25/2008WO2007146349A3 Cgrp receptor antagonists
09/25/2008US20080234480 Triphendioxazine Pigments
09/25/2008US20080234256 Antibacterial Agents
09/25/2008US20080234250 Heterocyclic Condensed Compounds Useful as Antidiuretic Agents
09/24/2008EP1971612A1 8-pyrazinyl-s-spiropyrimidinetrione-oxazinoquinoline derivatives as antibacterial agents
09/24/2008EP1971608A1 Spiroketals
09/24/2008EP1971599A1 Antiviral 2-carboxy-thiophene compounds
09/24/2008EP1971596A2 Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
09/24/2008EP1971576A2 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
09/24/2008EP1509528B1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
09/23/2008US7427682 Indole derivatives as selective androgen receptor modulators (SARMS)
09/23/2008US7427681 Anticancer agents; antidiabetic agents; Alzheimer's disease
09/23/2008US7427637 Kinesin spindle protein (KSP) inhibitors; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator; e.g. bicyclic dihydropyrrole derivatives
09/23/2008US7427630 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one; potent; to treat central nervous system disorders; antidepressants; Anxiolytic agents; mood disorders; anagesics; gastrointestinal disorders like irritable bowel syndrome
09/23/2008US7427616 e.g. 8-(1-methyl-4-phenyl-1H-imidazol-5-yl)-9H-purin-6-amine9-methyl-8-(1-methyl-4-phenyl-1H-imidazol-5-yl)-9H-purin-6-amine; Tie2 receptor tyrosine kinase and angiogenesis inhibitor; diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma
09/23/2008US7427615 3-substituted-4-pyrimidone derivatives
09/23/2008CA2432872C Pyrazole compounds useful as protein kinase inhibitors
09/23/2008CA2354852C 4,5-azolo-oxindoles
09/23/2008CA2326222C Medicinal compositions
09/23/2008CA2173703C Synergistic stabilizer mixture
09/18/2008WO2008111630A1 Pirenoxine-containing suspension-type aqueous preparation
09/18/2008WO2008111473A1 Glucokinase activator
09/18/2008WO2008110611A1 Organic compounds and their uses
09/18/2008WO2008110583A1 Amide compounds and their use as antitumor agents
09/18/2008US20080227781 Imidazole compounds for the treatment of neurodegenerative disorders
09/18/2008US20080227765 Cytotoxic depsipeptides
09/18/2008CA2681162A1 Benzyl and pyridine derivatives as modulators of hedgehog pathway
09/18/2008CA2679971A1 Glucokinase activator
09/18/2008CA2677874A1 Amide compounds and their use as antitumor agents
09/17/2008EP1970373A1 Alicyclic heterocyclic compound
09/17/2008EP1968984A1 Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib
09/17/2008EP1968938A1 Substituted propiolic acid amides and their use for producing drugs
09/17/2008EP1968604A2 Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate
09/17/2008EP1968600A2 Rifamycin analogs and uses thereof
09/17/2008EP1968598A1 Pyrimidine-2,4-diamines and their uses
09/17/2008CN101268084A Caspase inhibitor prodrugs
09/17/2008CN101268077A Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
09/17/2008CN101268043A Amino-alkyl-amide derivatives as CCR3 receptor ligands
09/17/2008CN101267816A Methods of treatment using hydroquinone ansamycins
09/17/2008CN101265262A New oxabispidine compounds useful in the treatment of cardiac arrhythmias
09/16/2008US7425639 Process
09/16/2008US7425629 Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
09/16/2008US7425628 Levofloxacin has been purified by dissolving levofloxacin in a polar solvent at an elevated temperature and crystallizing purified levofloxacin. Preferably, an antioxidant is added to increase the purity.
09/16/2008US7425627 Methods of synthesizing olanzapine
09/16/2008US7425550 Lactam glycogen phosphorylase inhibitors and method of use
09/16/2008CA2515338C Inhibitors of histone deacetylase
1 ... 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 ... 220